Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $11.00 price target on the stock.
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies [Yahoo! Finance]
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results [Yahoo! Finance]
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results